YERVOY is a recombinant, human monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), a negative regulator of T-cell activation.
The US Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
Under the agreement, the two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination.
If appropriate, the companies may conduct further development of the combination.
The agreement represents an important cross-company collaboration exploring the potential role of this regimen in the treatment of metastatic melanoma.